bioRxiv · 10.1101/2024.10.11.617910
Single-molecule characterisation of soluble beta-amyloid aggregate binding by Aducanumab, Lecanemab, Gantenerumab, and Donanemab
Abstract
Monoclonal antibodies Aducanumab, Lecanemab, Gantenerumab, and Donanemab have been developed for treatment of Alzheimers disease. Here, we have used single-molecule detection techniques and super-resolution imaging to characterise the binding of these antibodies to beta-amyloid aggregates including human post-mortem brain samples. Lecanemab is the best antibody in terms of binding to the small-soluble beta-amyloid aggregates, affinity, aggregate coating, and the ability to bind to post-translationally modified species, explaining its therapeutic success.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Fertan, E., Lam, J. Y. L., Albertini, G., Dewilde, M., Wu, Y., Akingbade, O. E. S., Boeken, D., English, E. A., De Strooper, B., Klenerman, D.. 2024-10-12. Single-molecule characterisation of soluble beta-amyloid aggregate binding by Aducanumab, Lecanemab, Gantenerumab, and Donanemab. https://doi.org/10.1101/2024.10.11.617910
Cite the original work for its findings. Save a collection to share your selection of sources.